Document Classification

Section Type: RESULTS

Text: There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged < 75 years (1. 89 % versus 3. 04 % ; P < 0. 001) and a similar risk in those aged 75 years (4. 43 % versus 4. 37 % ; P = 0. 89 ; P for interaction < 0. 001), whereas dabigatran 150 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in those aged < 75 years (2. 12 % versus 3. 04 % ; P < 0. 001) and a trend toward higher risk of major bleeding in those aged 75 years (5. 10 % versus 4. 37 % ; P = 0. 07 ; P for interaction < 0. 001).